Phreesia (NYSE:PHR) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Phreesia (NYSE:PHR) announced its quarterly earnings results on Monday. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04, Briefing.com reports. The business had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. Phreesia’s quarterly revenue was up 16.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.58) EPS. Phreesia updated its FY 2026 guidance to EPS and its FY 2025 guidance to EPS.

Phreesia Price Performance

Shares of NYSE:PHR opened at $21.63 on Tuesday. The firm has a 50 day moving average of $20.26 and a 200-day moving average of $21.75. Phreesia has a 12 month low of $17.07 and a 12 month high of $29.16. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $1.25 billion, a PE ratio of -12.02 and a beta of 0.98.

Analyst Upgrades and Downgrades

PHR has been the topic of several research reports. Robert W. Baird upped their target price on Phreesia from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Friday, September 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $23.00 price objective on shares of Phreesia in a report on Friday, September 27th. Truist Financial lifted their target price on Phreesia from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, September 6th. Canaccord Genuity Group restated a “buy” rating and issued a $34.00 price target on shares of Phreesia in a research note on Thursday, September 5th. Finally, JPMorgan Chase & Co. raised their price target on shares of Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Monday, September 9th. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.42.

Insider Buying and Selling

In related news, General Counsel Allison C. Hoffman sold 1,212 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $21.03, for a total value of $25,488.36. Following the sale, the general counsel now directly owns 119,791 shares of the company’s stock, valued at $2,519,204.73. This trade represents a 1.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Yvonne Hui sold 2,791 shares of Phreesia stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.92, for a total value of $58,387.72. Following the completion of the transaction, the insider now owns 27,228 shares in the company, valued at approximately $569,609.76. This represents a 9.30 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 53,569 shares of company stock worth $1,123,014. Corporate insiders own 5.80% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.